SAMUEL ABSHIRE: Open Payments
NPI 1407883820 · HAYNESVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$335 in 17 payments from 9 companies in 2025. Trend: 2023 $529 · 2024 $745 · 2025 $335
Food & beverage: $335
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Braeburn Inc. | 1 | $16 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: Kerendia, CAPLYTA, Auvelity, AIRSUPRA, REXULTI, MOUNJARO, LEQVIO, BRIXADI.
Industry payments across LA — which companies pay providers there.
